Scarica l'app Stockscreener
6.65
7.77%
-0.56
Dopo l'orario di chiusura:
6.65
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$7.21
Aprire:
$7
Volume 24 ore:
993.61K
Relative Volume:
1.25
Capitalizzazione di mercato:
$448.30M
Reddito:
$8.78M
Utile/perdita netta:
$-104.70M
Rapporto P/E:
-2.8059
EPS:
-2.37
Flusso di cassa netto:
$-82.68M
1 W Prestazione:
-19.78%
1M Prestazione:
-15.29%
6M Prestazione:
-45.89%
1 anno Prestazione:
-50.74%
Intervallo 1D:
$6.60
$7.08
Intervallo di 1 settimana:
$6.60
$8.34
Portata 52W:
$6.60
$17.58
Stoke Therapeutics Inc Stock (STOK) Company Profile
Nome
Stoke Therapeutics Inc
Settore
Industria
Telefono
781-430-8200
Indirizzo
45 WIGGINS AVENUE, BEDFORD, MA
Confronta STOK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
6.65 | 448.30M | 8.78M | -104.70M | -82.68M | -2.37 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-20 | Iniziato | Chardan Capital Markets | Buy |
| 2024-10-14 | Ripresa | Leerink Partners | Outperform |
| 2024-03-26 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-07-25 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-04-26 | Ripresa | Canaccord Genuity | Buy |
| 2023-01-06 | Downgrade | BofA Securities | Buy → Underperform |
| 2022-10-24 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | Iniziato | Jefferies | Buy |
| 2021-12-03 | Iniziato | BofA Securities | Buy |
| 2021-11-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-05-18 | Iniziato | UBS | Neutral |
| 2021-05-10 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-02-10 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-12-15 | Ripresa | H.C. Wainwright | Buy |
| 2020-12-11 | Reiterato | Needham | Buy |
| 2020-10-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-09-29 | Iniziato | Needham | Buy |
| 2019-12-18 | Iniziato | Wedbush | Outperform |
| 2019-11-12 | Iniziato | BTIG Research | Buy |
| 2019-10-25 | Iniziato | H.C. Wainwright | Buy |
| 2019-07-15 | Iniziato | Canaccord Genuity | Buy |
| 2019-07-15 | Iniziato | Cowen | Outperform |
| 2019-07-15 | Iniziato | Credit Suisse | Outperform |
| 2019-07-15 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Stoke Therapeutics Inc Borsa (STOK) Ultime notizie
Swiss National Bank Acquires 11,400 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics stock hits 52-week low at $7.20 amid market challenges By Investing.com - Investing.com South Africa
Stoke Therapeutics stock hits 52-week low at $7.20 amid market challenges - Investing.com
Dravet Syndrome Market Expected to Experience Major Growth - openPR.com
Bank of New York Mellon Corp Acquires 1,330 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
(STOK) Technical Data - news.stocktradersdaily.com
Cantor Fitzgerald Issues Positive Forecast for STOK Earnings - Defense World
Wedbush Equities Analysts Raise Earnings Estimates for STOK - Armenian Reporter
Earnings Beat: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Yahoo
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Brokers Offer Predictions for STOK Q3 Earnings - Defense World
What is Leerink Partnrs’ Forecast for STOK Q1 Earnings? - Defense World
Q1 EPS Estimates for Stoke Therapeutics Increased by Wedbush - Defense World
Stoke Therapeutics general counsel sells shares totaling $35,731 By Investing.com - Investing.com South Africa
Stoke Therapeutics (NASDAQ:STOK) Earns Buy Rating from Chardan Capital - Defense World
Stoke Therapeutics (NASDAQ:STOK) Earns “Buy” Rating from HC Wainwright - Defense World
Analysts Issue Forecasts for STOK Q1 Earnings - Defense World
Stoke therapeutics’ chief medical officer sells $61,238 in stock By Investing.com - Investing.com South Africa
Stoke Therapeutics general counsel sells shares totaling $35,731 - Investing.com
Stoke Therapeutics director Kaye Edward M. sells shares worth $163,672 - Investing.com
Stoke therapeutics’ chief medical officer sells $61,238 in stock - Investing.com India
Stoke Therapeutics Executives Sell Shares for Tax Liabilities - TradingView
Stoke Therapeutics director Kaye Edward M. sells shares worth $163,672 By Investing.com - Investing.com UK
The Escalator: Stoke Therapeutics, Merck, Sutro Biopharma and more - MM+M Online
After Securing Biogen Pact, Stoke’s CEO Edward Kaye Bows Out - insights.citeline.com
Stoke Therapeutics announces CEO transition - The Pharma Letter
Stoke Therapeutics Inc (STOK) Q4 Earnings: EPS of -$0.18 Beats E - GuruFocus
Stoke Therapeutics (NASDAQ:STOK) Receives Buy Rating from Needham & Company LLC - Defense World
Analysts Offer Insights on Healthcare Companies: Intensity Therapeutics, Inc. (INTS) and Stoke Therapeutics (STOK) - The Globe and Mail
Stoke Therapeutics, Inc. SEC 10-K Report - TradingView
Forecasting The Future: 7 Analyst Projections For Stoke Therapeutics - Benzinga
Ed Kaye, founding CEO of Stoke Therapeutics, steps down - The Business Journals
Stoke Therapeutics Slips as CEO Steps Down - MSN
Stoke Therapeutics falls as CEO steps down amid earnings beat By Investing.com - Investing.com Canada
Stoke Therapeutics falls as CEO steps down amid earnings beat - Investing.com India
Stoke CEO Ed Kaye to depart shortly after inking Biogen pact and before its first Phase 3 trial - Endpoints News
Stoke Therapeutics CEO Edward Kaye Steps Down; Interim CEO Named -March 18, 2025 at 08:02 am EDT - MarketScreener
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Stoke Therapeutics appoints interim CEO amid leadership shuffle - Investing.com
Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - BioSpace
Stoke Therapeutics Announces 2024 Financial Results and Updates - TipRanks
Stoke Therapeutics Appoints Director Ian F. Smith Interim Chief Executive Officer -March 18, 2025 at 06:59 am EDT - Marketscreener.com
Stoke Therapeutics Inc Q4 Loss Decreases, Beats Estimates - Nasdaq
Stoke Therapeutics earnings beat by $0.37, revenue topped estimates - Investing.com UK
Stoke Therapeutics Announces CEO Transition - Business Wire
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
Stoke Therapeutics (STOK) to Release Quarterly Earnings on Monday - Defense World
Rhumbline Advisers Acquires 2,787 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Los Angeles Capital Management LLC Has $479,000 Stake in Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat
Stoke, Biogen team to advance zorevunersen for Dravet patients - Dravet Syndrome News
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Stoke Therapeutics Inc Azioni (STOK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.05%
1.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):